Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

ClinicalTrials.gov ID: NCT05268016

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05268016. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Efficacy and Safety of ME3183 Administered Orally in Subjects With Moderate to Severe Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults.

Study identification

NCT ID: NCT05268016
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Meiji Pharma USA Inc.; Industry
Enrollment: 132 participants

Conditions and interventions

Conditions

Plaque Psoriasis

Interventions

ME3183 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 24, 2022 (Actual)
Primary completion: May 31, 2023 (Actual)
Completion: May 31, 2023 (Actual)
Last update posted: Jun 27, 2024

2022 – 2023

United States locations

U.S. sites: 14
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
Northwest Arkansas Clinical Trials Center	Rogers	Arkansas	72758	—
University of Southern California	Los Angeles	California	90033	—
Colorado Medical Research Center, Inc.	Denver	Colorado	80210	—
International Dermatology Research, INC	Miami	Florida	33144	—
Qualmedica Research, LLC	Evansville	Indiana	47715	—
Owensboro Dermatology Associates	Owensboro	Kentucky	42303	—
Shondra L. Smith, MD Dermatology & Advanced Aesthetics	Lake Charles	Louisiana	70605	—
Skin Search of Rochester, Inc.	Rochester	New York	14623	—
Tennessee Clinical Research Center	Nashville	Tennessee	37215	—
Studies in Dermatology, LLC	Cypress	Texas	77433	—
Dermatology Treatment and Research Center	Dallas	Texas	75230	—
Center for Clinical Studies LTD, LLP	Houston	Texas	77004	—
Dermatology Clinical Research Center of San Antonio	San Antonio	Texas	78229	—
Premier Clinical Research	Spokane	Washington	99202	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05268016, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 27, 2024 · Synced Nov 12, 2026